

Special Issue

Prostate Cancer Metastasis— Diagnosis and Treatment

Message from the Guest Editor

The aim of this Special Issue is to share the latest developments in the detection of metastasis in advanced prostate cancer. This may be an early event after primary curative treatment, the early detection of hormone-sensitive metastatic disease—whether it is oligometastatic or extensively metastatic—or the various stages of castration-resistant prostate cancer. There may be exclusive treatment options for non-metastatic CRPC and CRPC after one or several previous lines of treatment. Recent developments also include biomarker-based treatment, which predicts the applicability and prognosis of certain treatments. Last but not least, the recent addition of novel hormone treatments, chemotherapy, PSMA ligands, and genetic-based treatment modalities has led to the question of optimal sequences. In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Guest Editor

Prof. Dr. Arnulf Stenzl
University of Tuebingen Hospital, 72076 Tuebingen, Germany

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223963

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)